# 1 Title: Performance characteristics of the VIDAS<sup>®</sup> SARS-COV-2 IgM and IgG

- 2 serological assays
- 3

## 4 Running title: VIDAS<sup>®</sup> SARS-COV-2 IgM and IgG assay performance

- 5
- 6 Nathalie Renard<sup>a#</sup>, Soizic Daniel<sup>a</sup>, Nadège Cayet<sup>a</sup>, Matthieu Pecquet<sup>b</sup>, Frédérique Raymond<sup>a</sup>,
- 7 Sylvie Pons<sup>c</sup>, Julien Lupo<sup>d</sup>, Carole Tourneur<sup>a</sup>, Catherine Pretis<sup>a</sup>, Guillaume Gerez<sup>a</sup>, Patrick Blasco<sup>a</sup>,
- 8 Maxime Combe<sup>a</sup>, Imen Canova<sup>a</sup>, Mylène Lesénéchal<sup>a#</sup>, Franck Berthier<sup>a</sup>
- 9
- <sup>a</sup>R&D bioMérieux, 376 Chemin de l'orme, 69280 Marcy l'Etoile, FRANCE
- <sup>11</sup> <sup>b</sup>Laboratoire de Biologie, Centre Hospitalier Saint Joseph Saint Luc, 20 Quai Claude Bernard,
- 12 69007 Lyon, FRANCE
- 13 <sup>c</sup>Laboratoire commun de recherche Hospices Civils de Lyon bioMérieux, Centre Hospitalier
- 14 Lyon-Sud, Bâtiment 3F, Chemin du Grand Revoyet, 69310 Pierre-Bénite, FRANCE
- <sup>d</sup>Institut de Biologie Structurale (IBS), CEA, CNRS, Université Grenoble-Alpes; Laboratoire de Virologie,
- 16 Centre hospitalier Universitaire Grenoble-Alpes, CS10217, 38043 Grenoble cedex 09, FRANCE
- 17
- 18 <sup>#</sup>Nathalie Renard : <u>Nathalie.RENARD@biomerieux.com</u>
- 19 <sup>#</sup>Mylène Lesénéchal : <u>mylene.lesenechal@biomerieux.com</u>

It is made available under a CC-BY-ND 4.0 International license .

#### 21 ABSTRACT

The COVID-19 pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 22 (SARS-CoV-2), continues to spread worldwide. Serological testing for SARS-CoV-2-specific 23 antibodies plays an important role in understanding and controlling the pandemics, notably 24 through epidemiological surveillance. Well validated and highly specific SARS-CoV-2 serological 25 26 assays are urgently needed. We describe here the analytical and clinical performance of VIDAS<sup>®</sup> 27 SARS-CoV-2 IgM and VIDAS<sup>®</sup> SARS-CoV-2 IgG, two CE-marked, EUA-authorized, automated, qualitative assays for the detection of SARS-CoV-2-specific IgM and IgG, respectively. Both 28 assays showed high within-run and within-laboratory precision (coefficients of variation < 29 11.0%) and very low cross-reactivity towards sera of patients with a past common coronavirus 30 or respiratory virus infection. Clinical specificity determined on up to 989 pre-pandemic healthy 31 32 donors was  $\geq$  99% with a narrow 95% confidence interval for both IgM and IgG assays. Clinical sensitivity was determined on up to 232 samples from 130 RT-PCR-confirmed SARS-CoV-2 33 patients. The positive percent agreement (PPA) with SARS-CoV-2 PCR reached 100% at  $\geq$  16 days 34 (VIDAS<sup>®</sup> SARS-CoV-2 |gM) and  $\geq$  32 days (VIDAS<sup>®</sup> SARS-CoV-2 |gG) of symptom onset. Combined 35 IgM/IgG test results improved the PPA compared to each test alone. SARS-CoV-2 IgG 36 37 seroconversion followed closely that of SARS-CoV-2 IgM and remained stable over time, while SARS-CoV-2 IgM levels rapidly declined. Interestingly, SARS-CoV-2-specific IgM and IgG 38 responses were significantly higher in COVID-19 hospitalized vs. non-hospitalized patients. 39 Altogether, the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays are highly specific and sensitive 40 serological tests suitable for the reliable monitoring of past SARS-CoV-2 infections and for 41 seroepidemiology investigations. 42

It is made available under a CC-BY-ND 4.0 International license .

#### 43 INTRODUCTION

Coronavirus disease 19 (COVID-19) is an infectious disease caused by the newly discovered 44 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1, 2). Within three months of its 45 emergence in China in December 2019, COVID-19 has been declared a global pandemic by the 46 World Health Organisation (WHO). As of September 25, 2020, nearly 32 million COVID-19 cases 47 and 980,000 deaths have been reported worldwide (3-5). Accurate diagnosis is essential in 48 49 managing the pandemic, not only to identify, isolate and treat affected patients, but also to characterize the epidemiology of virus transmission and develop national and international 50 surveillance programs. WHO recommends molecular testing of SARS-CoV-2 nucleic acids for 51 acute-phase diagnosis of suspected cases (6–8). Several nucleic acid amplification tests (NAATs), 52 53 mostly based on guantitative reverse transcriptase polymerase chain reaction (RT-gPCR), have 54 received the Conformité Européenne (CE) mark and have been approved by the United States 55 Food and Drug Administration (FDA) under emergency use authorization (EUA) (9–11). On the other hand, serological testing for SARS-CoV-2-specific antibodies, especially immunoglobulin M 56 (IgM) and immunoglobulin G (IgG), is not recommended for the diagnosis of acute cases. It plays 57 58 however an essential role in the diagnosis of past SARS-CoV-2 infection and in ongoing 59 immunological and epidemiological surveillance. Serological testing might also complement molecular testing to confirm suspected cases not detected by molecular assays, either due to 60 late (> 7 days after infection) or improper sample collection. Finally, serology screening may 61 allow the identification of convalescent plasma donors for use as potential therapy against 62 COVID-19 (9-21). 63

SARS-CoV-2 serological testing is facing several challenges. Among them, sensitivity and 64 specificity should be well defined for the target population and validated at different post-65 66 infection time windows. Specificity is particularly critical in the current pandemic phase, as seroprevalence in the population is still low. In such low-incidence settings, a specificity > 99% 67 and a narrow 95% confidence interval (95% CI) are required to ensure a high positive predictive 68 69 value (PPV) (11, 22, 23). Accordingly, the antigens used to design serology tests should be 70 properly selected and cross-reactivity with antibodies directed against other antigens, including from other coronaviruses, should be verified. A huge number of serology assays have been 71 72 developed and marketed in the last few months, of which 38 received FDA's EUA (as of August 73 31, 2020) (24, 25). Clinical performance data of commercial tests are still scant, and examples of 74 poorly performing tests have even been reported (9). Therefore, there is an urgent need for well 75 validated and performant serology tests, notably demonstrating very high specificity.

We describe here the analytical and clinical performance of VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-CoV-2 IgG, two CE-marked and EUA-authorized automated qualitative assays for the detection of SARS-CoV-2-specific IgM and IgG, respectively, in serum or plasma. Kinetics of SARS-CoV-2-specific IgM and IgG seroconversion using the VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-CoV-2 IgG assays were also compared in hospitalized and non-hospitalized COVID-19 patients.

It is made available under a CC-BY-ND 4.0 International license .

#### 82 MATERIALS AND METHODS

#### 83 Patients and samples.

SARS-CoV-2-positive samples were collected after approval by the French national review board for biomedical research in April 2020 (Comité de Protection des Personnes Sud Méditerranée I, Marseille, France) under the number ID RCB 2020-A00932-37. The international trial registration number in ClinicalTrial.gov is NCT04341142. Informed consent was obtained in accordance with the local regulations. Pre-pandemic samples (from healthy subjects and from donors with other medical conditions) were collected in accordance with the Declaration of Helsinki, as revised in 2013. Collected sera and plasma were stored frozen (< -20°C) until further testing.

Serum from up to 989 healthy pre-pandemic adult donors collected before September 2019 at two geographical sites (Etablissement Français du Sang (EFS), France; Clinilabs, Inc., United States) were used to determine the assay specificity of the VIDAS® SARS-CoV-2 IgM, IgG and combined IgM/IgG test (defined as negative if both VIDAS® SARS-CoV-2 IgM and IgG assays are negative).

For the evaluation of the positive percent agreement (PPA), 405 serum or plasma samples from 142 hospitalized and non-hospitalized symptomatic patients diagnosed with COVID-19 and confirmed positive for SARS-CoV-2 by molecular testing (cobas® SARS-CoV-2, Roche 09175431190 or Real-time RT-PCR assays for the detection of SARS-CoV-2 Institut Pasteur, Paris (26), performed at the collection site) were collected at three local hospitals (Centre Hospitalier Saint Joseph Saint Luc, Lyon, France; Centre de Ressources Biologiques [CRB] des Hospices Civils de Lyon, CRB Nord and CRB Sud, Lyon, France) between March 31 and June 2, 2020. Samples

were tested with the VIDAS® SARS-CoV-2 IgM and IgG assays, and paired measurements were considered for the combined IgM/IgG test results (defined as positive if at least one of the VIDAS® SARS-CoV-2 IgM and/or IgG assays is positive). The PPA was evaluated according to weekly time frames (0-7, 8-15, 16-23, 24-31,  $\geq$  32 days) relative to the time from RT-PCR positive result and from symptom onset, when documented.

For the evaluation of serum cross-reactivity, up to 276 frozen pre-pandemic sera (i.e. negative for SARS-CoV-2) collected from patients with other potentially interfering infections or medical conditions (bioMérieux, Centre Hospitalier Universitaire Grenoble-Alpes and St Joseph St Luc Lyon collections) were tested with the VIDAS® SARS-CoV-2 IgM (276 sera from 33 medical conditions; one to 30 sera per condition) and the VIDAS® SARS-CoV-2 IgG (261 sera from 33 medical conditions; two to 30 sera per condition) assays.

114

#### 115 Serological assays.

VIDAS<sup>®</sup> SARS-CoV-2 lgM (423833) and VIDAS<sup>®</sup> SARS-CoV-2 lgG (423834) (bioMérieux, France) 116 are automated gualitative CE-IVD assays developed for the VIDAS® family of instruments and 117 118 based on a two-step enzyme immunoassay combined with an enzyme-linked fluorescent assay (ELFA) detection technique. The VIDAS<sup>®</sup> SARS-CoV-2 lgM and VIDAS<sup>®</sup> SARS-CoV-2 lgG assays are 119 120 intended for use as an aid to determine if individuals may have been exposed and infected by 121 SARS-CoV-2 and if they have mounted a specific anti-SARS-CoV-2 lgM and lgG immune response. These assays allow the detection of SARS-CoV-2-specific IgM and IgG, respectively, 122 from 100 µl serum or plasma (lithium heparin). The VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-123

CoV-2 lgG serological assays were conducted according to the manufacturer's instructions. 124 125 Briefly, a solid-phase receptacle coated with the antigen (recombinant SARS-CoV-2 receptor-126 binding domain [RBD] of the viral Spike protein) serves as both solid phase and pipetting device. 127 After the sample dilution step, SARS-CoV-2-specific IgM and IgG are captured on the coated antigen and unbound components are washed out. In a second step, human IgM (VIDAS® SARS-128 129 CoV-2 IgM) or IgG (VIDAS<sup>®</sup> SARS-CoV-2 IgG) are specifically detected by mouse monoclonal 130 antibodies conjugated to alkaline phosphatase and directed against human IgM or IgG, respectively. Unbound components are eliminated by washing and detection is performed by 131 132 incubation with the substrate (4-Methyl-umbelliferyl phosphate) followed by measurement of the fluorescent product (4-Methyl-umbelliferone) at 450 nm. A relative fluorescence value (RFV) 133 134 is generated (background reading subtracted from the final fluorescence reading). The assay is 135 conducted with a standard (S1) and a positive control (C1) that contains humanized recombinant anti-SARS-CoV-2 antibody, either IgM or IgG depending on the assay. A negative 136 control (C2) is also supplied. The results are automatically calculated by the instrument, 137 according to the S1 standard, and an index value (i) is obtained (where i=RFV<sub>sample</sub>/RFV<sub>S1</sub>). The 138 139 test is interpreted as negative when i < 1.00 and positive when  $i \ge 1.00$ . The positivity cut-off 140 values for the IgM and IgG tests were determined from a healthy pre-pandemic cohort (259 141 [IgM test] and 120 [IgG test] samples collected prior to August 2019), using non-parametric 99<sup>th</sup> percentile because of normality rejection for the IgM positivity cut-off and using the (99,99) 142 tolerance intervals approach after Box-Cox transformation (27) for the IgG positivity cut-off (99<sup>th</sup> 143 percentile index values at a 99% confidence level) (data not shown). 144

145

It is made available under a CC-BY-ND 4.0 International license .

146

147

#### 148 **Statistical analysis.**

149 IgG positivity cut-off values were determined by the tolerance intervals approach (28) and the 150 parametric method using the Analyse-it 5.40 and JMP 13.1.0 software. IgM positivity cut-off 151 values were determined by the non-parametric 99<sup>th</sup> percentile using the Analyse-it 5.40 152 software.

Assay precision (repeatability or within-run precision, and within-laboratory precision) were evaluated according to the Clinical & Laboratory Standards Institute (CLSI) EP05-A3 guideline (29) by the variance component method and restricted maximum likelihood (REML) using the SAS Enterprise Guide 7.13 HF8 software.

Specificity and sensitivity (PPA) estimates were evaluated according to the CLSI EP12-A2 guideline (30). The 95% confidence intervals (95% CI) were computed (either as score confidence interval if the specificity or sensitivity (PPA) belonged to ] 5 ; 95[%, or as exact confidence interval otherwise) using the SAS Enterprise Guide 7.13 HF8 software.

PPA was evaluated per time windows (in days) relative to the day of RT-PCR positive result and of symptom onset (when documented). Only one patient's measurement per time period was included in the analysis. In case of multiple patient's measurements in one period, the first available measurement was considered for the calculation.

165 The positive predictive value (PPV) and the negative predictive value (NPV) were calculated 166 assuming a prevalence of 5%, as recommended by FDA for the EUA application (25), and the

It is made available under a CC-BY-ND 4.0 International license .

respective 95% CI were computed according to Mercaldo et al. (31) using the SAS Enterprise
Guide 7.13 HF8 software.

VIDAS<sup>®</sup> SARS-CoV-2 index values were displayed per time frame as Tukey box plots showing 169 median values (horizontal line), interquartile ranges (IQR: Q3-Q1), lower and upper whiskers 170 (Q1-1.5xlQR and Q3+1.5xlQR respectively) and outliers (below Q1-1.5xlQR and above 171 172 Q3+1.5xlQR; black dots). Two-group comparisons of index values per time frame between hospitalized and non-hospitalized patients were performed using the nonparametric two-tailed 173 174 Mann-Whitney U-test (MWU-test) with normal approximation. The Bonferroni method was 175 applied for controlling the 5% overall probability of a false-significant result when multiple 176 comparisons were carried out; given that three comparisons were performed, P-values < 0.017 177 (one third of 0.05) were considered statistically significant.

It is made available under a CC-BY-ND 4.0 International license .

#### 179 **RESULTS**

## 180 Analytical performance of VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays

Within-run and within-laboratory precisions of the ELFA-based tests were determined using 181 three samples (one negative and two positive for SARS-CoV-2 IgM and IgG). Samples were run in 182 triplicate on one VIDAS<sup>®</sup> instrument, twice a day over 10 days (with an instrument calibration 183 184 every second day), using one assay lot, thus generating 60 measurement values per sample. The 185 coefficient of variation (%CV) for repeatability (within-run precision) did not exceed 9.3% and 5.9% for the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays, respectively. The %CV for within-laboratory 186 precision was also low, reaching a maximum of 10.7% and 6.9% for the VIDAS<sup>®</sup> SARS-CoV-2 IgM 187 and IgG assays, respectively (Table 1). 188

Analytical specificity and sensitivity of the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays were verified 189 through various experiments. First, we ruled out a possible cross-reactivity of the anti-human-190 IgM (VIDAS<sup>®</sup> SARS-CoV-2 IgM) or of the anti-human-IgG (VIDAS<sup>®</sup> SARS-CoV-2 IgG) with human 191 192 IgG or IgM, respectively, which might produce false-positive results. Spike-in experiments in negative samples using either human recombinant monoclonal anti-SARS-CoV-2 lgG (in the 193 VIDAS<sup>®</sup> SARS-CoV-2 IgM assay) or human recombinant monoclonal anti-SARS-CoV-2 IgM (in the 194 VIDAS<sup>®</sup> SARS-CoV-2 IgG assay) demonstrated neither reactivity of the alkaline-phosphatase-195 196 conjugated anti-human-lgM toward human lgG nor reactivity of the anti-human-lgG toward 197 human IgM (data not shown). Second, we ruled out a possible competition between anti-SARS-198 CoV-2 IgM and IgG for binding to the coated SARS-CoV-2 antigen, which might interfere with the 199 respective assays and generate false-negative results. Spike-in experiments in positive samples using increasing amounts of human recombinant monoclonal anti-SARS-CoV-2 lgG (in the 200

VIDAS<sup>®</sup> SARS-CoV-2 IgM assay) or of human recombinant monoclonal anti-SARS-CoV-2 IgM (in 201 the VIDAS<sup>®</sup> SARS-CoV-2 IgG assay) did not impact the test results (data not shown). Third, we 202 203 evaluated the impact of serum inactivation (56°C for 30 minutes), which might be applied by diagnostics laboratories to inactivate potentially infectious samples (32), on test results of 204 negative and positive samples. Heat inactivation affected significantly VIDAS<sup>®</sup> SARS-CoV-2 lgM 205 206 and IgG assay outcome (data not shown) and should therefore be avoided. Finally, we evaluated the possible cross-reactivity of components of the assay (SARS-CoV-2 antigen RBD or 207 208 immunoglobulins) with human sera from patients with other infections (including other 209 coronaviruses) or medical conditions (e.g. rheumatoid factor) (33) that might interfere with the assay and yield false-positive results. Up to 276 (VIDAS<sup>®</sup> SARS-CoV-2 IgM) and 261 (VIDAS<sup>®</sup> SARS-210 211 CoV-2 lgG) sera of SARS-CoV-2-negative patients with other infections or conditions were tested and the number of positive test results was evaluated (Table 2). None of the 18 sera of patients 212 with an history of infection with the human coronaviruses CoV-NL63, CoV-229E, CoV-HKU1 or 213 CoV-OC43 (genera Alphacoronavirus and Betacoronavirus) were positive in the VIDAS<sup>®</sup> SARS-214 CoV-2 lgG assay, while the serum of one CoV-NL63-positive patient was positive in the VIDAS" 215 SARS-CoV-2 IgM assay. Only two out of 261 (0.8%) tested sera were positive in the VIDAS<sup>®</sup> SARS-216 CoV-2 IgG assay. They belonged to a HIV-positive and a respiratory syncytial virus (RSV A)-217 218 positive patient, respectively. On the other hand, ten out of 276 (3.6%) tested sera were positive in the VIDAS<sup>®</sup> SARS-CoV-2 IgM assay. Apart from the one CoV-NL63-positive sample 219 220 mentioned above, six sera were from patients presenting autoantibodies (antinuclear antibody, rheumatoid factor), two were from patients with an history of parasite infection (*Plasmodium* 221 falciparum, Trypanosoma cruzi), and one from a past Rhinovirus/Enterovirus infection. None of 222

It is made available under a CC-BY-ND 4.0 International license .

the sera from patients infected with other respiratory viruses, including influenza virus, parainfluenza virus, metapneumovirus or adenovirus were reactive.

225

## 226 Clinical performance of VIDAS<sup>®</sup> SARS-COV-2 IgM and IgG assays

The clinical specificity of the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays were assessed using sera 227 from 989 pre-pandemic healthy volunteers collected in France and in the United States before 228 229 September 2019. All 989 sera were tested with the VIDAS® SARS-CoV-2 IgG assay, while 308 230 samples were tested with the VIDAS<sup>®</sup> SARS-CoV-2 IgM assay. The combined IgM/IgG assay specificity (defined as both VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays being negative) was 231 determined on 308 paired VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG tests (Table S1 and Table 3). 232 306/308 (VIDAS<sup>®</sup> SARS-CoV-2 IgM) and 988/989 (VIDAS<sup>®</sup> SARS-CoV-2 IgG) SARS-CoV-2-negative 233 sera were negative, corresponding to a specificity (95% Cl) of 99.4% (97.7-99.9%) and 99.9% 234 (99.4-100%) for the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays, respectively (Table 3). The 235 specificity (95% CI) of the VIDAS<sup>®</sup> SARS-CoV-2 lgG test on the common cohort (N=308) was 236 100.0% (98.8-100.0%). The specificity (95% CI) of the combined IgM and IgG serology tests 237 (306/308 tests negative in both assays) was 99.4% (97.7-99.9%) (Table 3). 238

The clinical sensitivity of the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays was assessed using 405 samples collected from 142 patients confirmed positive for SARS-CoV-2 by RT-PCR. The positive percent agreement (PPA) of the serology tests with the RT-PCR test results was calculated per weekly time windows (0-7, 8-15, 16-23, 24-31 and  $\geq$  32 days) relative to the time from the PCRpositive result and to the time from symptom onset. No more than one patient sample per time window was included in the calculation (Fig. 1 and Table S2). The PPA calculated on all available samples for the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays are shown in Tables S3 and S4, respectively. For the sake of comparability, the PPA of the IgM, IgG and combined IgM/IgG test results was also calculated on paired samples (i.e. tested with both the IgM and IgG assays; Tables 4 and 5).

249 The PPA (95% CI) from the time of RT-PCR-positive test results raised from 44.5% (35.6-53.9%) 250 and 45.5% (36.5-54.8%) at 0-7 days, to 81.7% (70.1-89.4%) and 88.3% (77.8-94.2%) at 8-15 days, to 81.6% (66.6-90.8%) and 94.7% (82.7-98.5%) at 16-23 days, to 100.0% (75.3-100.0%) and 251 100.0% (75.3-100.0%) at 24-31 days, and to 81.8% (52.3-94.9%) and 100.0% (71.5-100.0%) at ≥ 252 32 days for the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays, respectively (Table 4). The PPA (95% CI) 253 254 of the combined IgM and IgG serology tests (positive in at least one of the IgM and/or IgG 255 assays) from the time of RT-PCR-positive test results, increased from 53.6% (44.4-62.7%) at 0-7 days, to 95.0% (86.1-99.0%) at 8-15 days, up to 100.0% at 16-23 days, 24-31 days and  $\geq$  32 days 256 257 (with respective 95% CI of 90.7-100.0%, 75.3-100.0% and 71.5-100.0%) (Table 4). The PPA (95% Cl) evaluated relative to the time of symptom onset raised from 31.8% (16.4-52.7%) and 31.8% 258 (16.4-52.7%) at 0-7 days, to 82.8% (65.5-92.4%) and 86.2% (69.4-94.5%) at 8-15 days, to 100.0% 259 260 (86.8-100.0%) and 96.2% (80.4-99.9%) at 16-23 days, to 100.0% (81.5-100.0%) and 94.4% (74.2-99.0%) at 24-31 days, and to 100.0% (69.2-100.0%) and 100.0% (69.2-100.0%) at  $\geq$  32 days for 261 the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays, respectively (Table 5). The PPA (95% CI) of the 262 combined IgM and IgG serology test results from the time of symptom onset, increased from 263 36.4% (19.7-57.0%) at 0-7 days, to 89.7% (73.6-96.4%) at 8-15 days, up to 100.0% at 16-23 days, 264

It is made available under a CC-BY-ND 4.0 International license .

265 24-31 days and ≥ 32 days (with respective 95% Cl of 86.8-100.0%, 81.5-100.0% and 69.2-100.0%) 266 (Table 5).

Based on the specificity and sensitivity (i.e. PPA) determined on paired IgM and IgG testing 267 (N=308 for specificity; N=105 for PPA), the negative predictive value (NPV) and the positive 268 predictive value (PPV) were calculated at 5% prevalence (25), according to the time after 269 symptom onset (Table 6). The NPV was high for both the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG 270 271 assays, whether considered alone or in combination; NPV was  $\geq$  96.5% (lower 95% confidence limits ≥ 95.4%) at 0-7 days post symptom onset and NPV increased from 99.1% to 100.0% (lower 272 95% confidence limits ≥ 98.0%) from day 8 onwards following symptom onset. The PPV of the 273 VIDAS<sup>®</sup> SARS-CoV-2 lgG assay was 100% at all time frames considered. Of note, the PPV 274 calculated using the full data set for the VIDAS<sup>®</sup> SARS-CoV-2 lgG specificity determination 275 (N=989) was slightly lower, increasing from 94.3% at 0-7 days to 98.1% at  $\geq$  32 days (Table S5). 276 The PPV (95% CI) of the VIDAS<sup>®</sup> SARS-CoV-2 IgM assay was lower, ranging from 72.1% (36.3-277 278 92.1%) at 0-7 days to 89.0% (67.1-97.0%) from day 16 onwards following symptom onset (Table 279 6). The combination of IgM and IgG test results slightly improved the PPV and NPV of the SARS-CoV-2 IgM assay, and the NPV of the SARS-CoV-2 IgG assay. The SARS-CoV-2 IgG assay 280 281 performed best alone in terms of PPV (Table 6).

282

## 283 Longitudinal study of IgM and IgG seroconversion in hospitalized COVID-19 patients

The global distribution of VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG index values post symptom onset was compared among the 105 SARS-CoV-2-positive patients described in Table 5 (Fig. 2). IgM index

values increased from the second week of symptom onset (8-15 days) and peaked during the third week (16-23 days) before decreasing. In comparison, the IgG index values strongly increased from the second week of symptom onset and seemed to reach a plateau  $\geq$  32 days post symptom onset (Fig. 2).

The VIDAS® SARS-CoV-2 IgM and IgG index values were also compared between hospitalized 290 291 and non-hospitalized patients. Since the date of symptom onset was not documented in non-292 hospitalized patients (Table S2), the index values were compared relative to the time of the RT-PCR-positive results (Fig. 3). Interestingly, the distribution of index values between hospitalized 293 and non-hospitalized patients differ statistically from each other for both the VIDAS® SARS-CoV-294 2 IgM and IgG assays at the three compared time frames (0-7, 8-15 and 16-23 days post PCR-295 296 positive test; MWU-test p-values < 0.017). Median index values were higher in hospitalized versus non-hospitalized patients (Fig. 3). 297

298 Finally, IgM and IgG seroconversion was further investigated in four selected hospitalized patients with either early and/or repeated measurements over an extended period of time (up 299 300 to 74 days post symptom onset; Fig. 4). IgG seroconversion closely followed IgM seroconversion 301 in the second week of symptom onset (Fig. 4A-B), in line with the global profile shown in Figure 302 2. SARS-CoV-2 IgM index rapidly decreased concomitantly with the increase of SARS-CoV-2 IgG 303 index (Fig. 4B-D). In the three patients shown in Fig. 4B-D, SARS-CoV-2 IgM index decreased below the positivity cutoff (index = 1.00) 46 days after symptom onset. In contrast, SARS-CoV-2 304 305 IgG index values remained high and stable from approximately day 20 onward after symptom onset, at least up to 74 days. 306

307

It is made available under a CC-BY-ND 4.0 International license .

#### 308 DISCUSSION

309

We describe here the analytical and clinical performance of the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays. We demonstrate that both assays show high precision, and excellent analytical and clinical performances.

The rate of cross-reactivity with non-specific antibodies, including those of patients infected 313 with other coronaviruses, was very low in both VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays. This 314 315 weak cross-reactivity with other coronaviruses antibodies is likely due, at least in part, to the choice of the receptor-binding domain (RBD) of the viral Spike protein as SARS-CoV-2-specific 316 antigen. The RBD shows a high sensitivity in ELISA, higher than that of the SARS-CoV-2 S1 or NC 317 antigens (34–38). It also presents a weaker homology and significant structural divergences with 318 the RBD of other coronaviruses (39–42). Another advantage of using the RBD is that the viral 319 antigen generates neutralizing antibodies likely to provide protective immunity (41-48), as 320 previously demonstrated for SARS-CoV-1 (49–51). Beside its strong immunogenicity and 321 antigenicity, the RBD of SARS-CoV-1 has been shown to elicit antibody responses that persisted 322 many years after infection (44, 51), raising the possibility that it might also be the case for the 323 324 RBD of SARS-CoV-2. Recent studies in COVID-19 patients, notably in convalescent donors (52– 325 54), on the anti-RBD antibody dynamics post SARS-CoV-2 infection (45, 46), or demonstrating the persistence and expansion of SARS-CoV-2-specific memory lymphocytes (55), as well as the 326 stability of the IgG response detected with the VIDAS<sup>®</sup> SARS-CoV-2 IgG assay up to 74 days post-327 symptom onset in the present study, strongly support this proposition. Hence, a serology test 328 such as the VIDAS<sup>®</sup> SARS-CoV-2 lgG assay is likely to be suitable for the detection of protective 329

It is made available under a CC-BY-ND 4.0 International license .

immunity and the evaluation of the efficacy of future vaccines, which are mainly based on theRBD-containing Spike protein (56, 57).

The low cross-reactivity rate with non-specific sera probably explains the very high specificity ( $\geq$ 99%) and narrow 95% CI of both VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays. The VIDAS<sup>®</sup> SARS-CoV-2 IgG assay alone had a specificity close to 100%, slightly higher than that of the VIDAS<sup>®</sup> SARS-CoV-2 IgM assay.

The clinical sensitivity of the VIDAS<sup>®</sup> SARS-CoV-2 assays was evaluated in SARS-CoV-2-confirmed 336 symptomatic cases and was determined as positive percent agreement (PPA) with the RT-PCR 337 assay, at successive time frames post positive PCR and, alternatively, post symptom onset. The 338 PPA reached 100% at 16-23 days (VIDAS<sup>®</sup> SARS-CoV-2 IgM) and at ≥ 32 days (VIDAS<sup>®</sup> SARS-CoV-2 339 IgG) post-symptom onset. The combined VIDAS<sup>®</sup> SARS-CoV-2 IgM/IgG test evaluation improved 340 341 the PPA of the respective IgM and IgG tests by 3.5 to 6.9 percent points during the first two weeks (0-7 and 8-15 days) of symptom onset. Such improved sensitivity of the combined 342 IgM/IgG tests early after symptom onset might also be useful for the diagnosis of suspected 343 COVID-19 cases with negative PCR (13–15, 17, 19–21). 344

Overall, the clinical performance of the VIDAS<sup>®</sup> SARS-CoV-2 assays was excellent. It outperformed or was similar to that reported for existing EUA serological assays (25, 38, 58–66). The high specificity of the VIDAS<sup>®</sup> SARS-CoV-2 IgG assay alone should be well suited for epidemiological surveillance.

349

The kinetics of SARS-CoV-2 IgM and IgG seroconversion was also evaluated by monitoring 350 VIDAS<sup>®</sup> index values over time. VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG index values increased in the 351 352 second week after symptom onset. IgG index values strongly increased and remained high, as 353 IgM index values rapidly declined. These profiles are in agreement with those described in 354 recent publications (13, 34, 45, 46, 67–72). Interestingly, the magnitude of the antibody 355 response (index values) correlated with disease severity, as it was significantly higher in 356 hospitalized vs. non-hospitalized COVID-19 patients at the time frames investigated (0-7, 18-15 and 16-23 days after a PCR-positive test). This observation is in agreement with published 357 reports (11, 46, 72–75). 358

359

This study presents several limitations. First, assay sensitivity was evaluated on confirmed but 360 not on suspected SARS-CoV-2 cases (i.e. patients with symptoms but negative by PCR). It would 361 be interesting to evaluate and confirm the benefit of SARS-CoV-2 IgM and IgG serology to 362 complement PCR testing (13, 14, 20, 21). On the other hand, recent reports suggested that the 363 identification rate of false-negative PCR results using serology testing might be marginal, 364 between ~1% (23) and ~4% (72). Second, assay sensitivity was determined on symptomatic 365 (hospitalized and non-hospitalized) COVID-19 patients. The sensitivity of the VIDAS<sup>®</sup> SARS-CoV-2 366 367 IgM and IgG assays in asymptomatic SARS-CoV-2-infected individuals, who may represent most of the infected patients, remains to be evaluated. 368

369

It is made available under a CC-BY-ND 4.0 International license .

- 370 In conclusion, the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays are highly sensitive and specific assays
- 371 for reliable patient monitoring after acute SARS-CoV-2 infections (and likely after vaccination,
- 372 when available). Moreover, the VIDAS® SARS-CoV-2 IgG assay fulfils the specificity requirement
- 373 for its use in seroepidemiology studies and is well suited for the detection of past SARS-CoV-2
- 374 infections. Further studies are necessary to evaluate its suitability for the detection of SARS-
- 375 CoV-2 neutralizing antibodies and to define correlates of immune protection.

It is made available under a CC-BY-ND 4.0 International license .

#### 376 ACKNOWLEDGMENTS

This work was supported by bioMérieux. We thank the Etablissement Français du Sang, notably 377 378 Yves Mérieux, for providing samples. We thank all the members of R&D Immunoassay bioMérieux who took part in this work, i.e. the bioMolecule Engineering team, Prototyping, 379 Development and Verification teams. We warmly thank Nadia Piga and the biobank team for 380 381 collecting the samples in a short time frame. We are grateful to the bioMérieux Data Sciences 382 team for the calculations and statistical evaluation of the data, and to Victor Bondanese, Laurence Bridon and the Clinical Affairs team of bioMérieux for their help and technical support. 383 We thank Karen Brengel for her useful advices as well as Alice Banz for critically reading the 384 manuscript. The authors thank Dr. Anne Rascle of AR Medical Writing (Regensburg, Germany) 385 386 for providing medical writing support, which was funded by bioMérieux (Marcy L'Etoile, France) 387 in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

388

389 Conflict of interests' statement

390 JL declares received research funding from bioMérieux for this study.

391 MP declares a consulting contract with bioMérieux.

NR, SD, ND, FR, SP, CT, CP, GG, PB, MC, IC, ML and FB are employees from bioMérieux, an *in vitro* diagnostic company.

394

395 Contributions

It is made available under a CC-BY-ND 4.0 International license .

- 396 NR, SD, ML, CT, FB conceived the study; CP, GG, PB, MC conceived the study and performed the
- 397 serological assays. FR, SP, MP, JL collected patients' samples; NC, IC, NR, CT, ML, interpreted
- 398 the serological assays; all authors contributed to data acquisition, data analysis, and/or data
- interpretation, and all authors reviewed and approved the final manuscript.

It is made available under a CC-BY-ND 4.0 International license .

#### 401 **REFERENCES**

- 402 1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J,
- 403 Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu
- 404 L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 2020. A pneumonia outbreak associated with a new
- 405 coronavirus of probable bat origin. Nature 579:270–273.
- 2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. 2020. The
   species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it
- 408 SARS-CoV-2. Nat Microbiol 5:536–544.
- 409 3. World Health Organization. 2020. Coronavirus Disease (COVID-19) Situation Reports.
  410 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed:
  411 September 25, 2020.
- 412 4. Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in real time.
  413 Lancet Infect Dis 20:533–534.
- Johns Hopkins University. 2020. COVID-19 Resource Center. https://coronavirus.jhu.edu/map.html.
  Accessed: September25, 2020.
- 416 6. World Health Organization. 2020. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in
  417 suspected human cases. https://www.who.int/publications-detail-redirect/10665-331501. Accessed:
  418 September 25, 2020.
- 419 7. World Health Organization. 2020. Global surveillance for COVID-19 caused by human infection with
  420 COVID-19 virus: interim guidance. https://www.who.int/publications-detail-redirect/global-

It is made available under a CC-BY-ND 4.0 International license .

421 surveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-interim-guidance.

422 Accessed: August 20, 2020.

- 423 8. World Health Organization. 2020. Laboratory testing strategy recommendations for COVID-19:
- 424 interim guidance. https://www.who.int/publications-detail-redirect/laboratory-testing-strategy-

425 recommendations-for-covid-19-interim-guidance. Accessed: August 20, 2020.

426 9. Vashist SK. 2020. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.
427 Diagnostics 10:202.

428 10. Venter M, Richter K. 2020. Towards effective diagnostic assays for COVID-19: a review. J Clin Pathol
429 jclinpath-2020-206685.

- 430 11. Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, Wang C-B, Mancini N, Steele S, Adeli K.
  431 2020. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce
  432 evaluation of the latest evidence. Clinical Chemistry and Laboratory Medicine (CCLM) 58:1037–1052.
- 433 12. Winter AK, Hegde ST. 2020. The important role of serology for COVID-19 control. The Lancet
  434 Infectious Diseases \$1473309920303224.

435 13. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L,
436 Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. 2020. Profiling Early
437 Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis
438 https://doi.org/10.1093/cid/ciaa310.

439 14. Zhao R, Li M, Song H, Chen J, Ren W, Feng Y, Gao GF, Song J, Peng Y, Su B, Guo X, Wang Y, Chen J, Li
440 J, Sun H, Bai Z, Cao W, Zhu J, Zhang Q, Sun Y, Sun S, Mao X, Su J, Chen X, He A, Gao W, Jin R, Jiang Y,

It is made available under a CC-BY-ND 4.0 International license .

- Sun L. 2020. Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of
  infection. Clinical Infectious Diseases ciaa523.
- 443 15. Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jaton K, Greub G. 2020. Diagnostic strategies
- for SARS-CoV-2 infection and interpretation of microbiological results. Clinical Microbiology and
  Infection 26:1178–1182.
- 16. Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D, Grenfell B, Metcalf CJE, Mina M,
- 447 Barraquer IR, Salje H, Tam CC. 2020. Seroepidemiologic Study Designs for Determining SARS-COV-2
- 448 Transmission and Immunity. Emerg Infect Dis 26:1978–1986.
- 17. Espejo AP, Akgun Y, Al Mana AF, Tjendra Y, Millan NC, Gomez-Fernandez C, Cray C. 2020. Review of
  Current Advances in Serologic Testing for COVID-19. American Journal of Clinical Pathology 154:293–
  304.
- 452 18. Pancrazzi A, Magliocca P, Lorubbio M, Vaggelli G, Galano A, Mafucci M, Duranti D, Cortesi M,
- 453 Mazzeschi E, Fabbroni S, Viti G, Tartaglia Polcini A, Tripodo E, Sanchini P, Gervino S, Tacconi D, Dei S,
- 454 Mazzierli M, D'Urso A, Ognibene A. 2020. Comparison of serologic and molecular SARS-CoV 2 results
- 455 in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic
- 456 sensitivity. Clinical Biochemistry S0009912020307918.
- 457 19. Wang P. 2020. Combination of serological total antibody and RT-PCR test for detection of SARS-COV458 2 infections. Journal of Virological Methods 283:113919.
- 20. Zhang J, Zhang X, Liu J, Ban Y, Li N, Wu Y, Liu Y, Ye R, Liu J, Li X, Li L, Qin X, Zheng R. 2020. Serological
  detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. Int
  Immunopharmacol 88:106861.

It is made available under a	a CC-BY-ND	4.0 International	license
------------------------------	------------	-------------------	---------

.

462	21.	Liu R, Liu X, Yuan L, Han H, Shereen MA, Zhen J, Niu Z, Li D, Liu F, Wu K, Luo Z, Zhu C. 2020. Analysis
463		of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome
464		coronavirus 2 (SARS-CoV-2) infection diagnosis. Int Immunopharmacol 86:106746.
465	22.	Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Yap, Hayford K, Luquero FJ, Mina MJ,
466		Rodriguez-Barraquer I, Wu JT, Wade D, Vernet G, Leung DT. 2020. Serology for SARS-CoV-2:
467		Apprehensions, opportunities, and the path forward. Sci Immunol 5:eabc6347.
468	23.	Farnsworth CW, Anderson NW. 2020. SARS-CoV-2 Serology: Much Hype, Little Data. Clinical
469		Chemistry hvaa107.
470	24.	U.S. Food and Drug Administration. 2020. In Vitro Diagnostics EUAs. https://www.fda.gov/medical-
471		devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-
472		diagnostics-euas. Accessed: August 20, 2020.
473	25.	U.S. Food and Drug Administration. 2020. EUA Authorized Serology Test Performance.
474		https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-
475		authorizations-medical-devices/eua-authorized-serology-test-performance. Accessed: August 31,
476		2020.
477	26.	World Health Organization. Real-time RT-PCR assays for the detection of SARS-CoV-2 Institut
478		Pasteur, Paris. https://www.who.int/nepal/activities/supporting-elimination-of-kala-azar-as-a-
479		public-health-problem/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-
480		of-sars-cov-2-institut-pasteur-paris. Accessed: August 20, 2020.
481	27.	Dong X, Tsong Y, Shen M. 2015. Statistical considerations in setting product specifications. J
482		Biopharm Stat 25:280–294.

It is made available under a CC-BY-ND 4.0 International license .

- 28. Dong X, Tsong Y, Shen M, Zhong J. 2015. Using Tolerance Intervals for Assessment of Pharmaceutical
  Quality. Journal of Biopharmaceutical Statistics 25:317–327.
- 485 29. Clinical & Laboratory Standards Institute. EP05-A3: Evaluating Quantitative Measurement Precision,
- 486 3rd Edition. https://clsi.org/standards/products/method-evaluation/documents/ep05/. Accessed:
- 487 August 20, 2020.
- 488 30. Clinical & Laboratory Standards Institute. EP12-A2: User Protocol for Evaluation of Qualitative Test
   489 Performance, 2nd Edition. https://clsi.org/standards/products/method 490 evaluation/documents/ep12/. Accessed: August 20, 2020.
- 491 31. Mercaldo ND, Lau KF, Zhou XH. 2007. Confidence intervals for predictive values with an emphasis to
  492 case-control studies. Stat Med 26:2170–2183.
- 493 32. Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN. 2020. Heat Inactivation of Different
  494 Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological
  495 Diagnostics? Viruses 12:735.
- 496 33. Tate J, Ward G. 2004. Interferences in immunoassay. Clin Biochem Rev 25:105–120.

497 34. Ma H, Zeng W, He H, Zhao D, Yang Y, Jiang D, Zhou P, Qi Y, He W, Zhao C, Yi R, Wang X, Wang B, Xu Y,
498 Yang Y, Kombe AJK, Ding C, Xie J, Gao Y, Cheng L, Li Y, Ma X, Jin T. 2020. COVID-19 diagnosis and
499 study of serum SARS-CoV-2 specific IgA, IgM and IgG by chemiluminescence immunoanalysis.
500 medRxiv 2020.04.17.20064907.

35. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM, Sikkema RS, de
Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-Fidouh N, Reusken CBEM,
Bosch B-J, Drosten C, Koopmans MPG, Haagmans BL. 2020. Severe Acute Respiratory Syndrome

It is made available under a CC-BY-ND 4.0 International license .

- 504 Coronavirus 2–Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerg Infect Dis
  505 26.
- 506 36. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P, Chan JM-C, Chik TS-H,
- 507 Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip JD, Ng AC-K, Poon RW-S, Luo C-T, Cheng VC-C,
- 508 Chan JF-W, Hung IF-N, Chen Z, Chen H, Yuen K-Y. 2020. Temporal profiles of viral load in posterior
- 509 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an
- 510 observational cohort study. Lancet Infect Dis 20:565–574.
- 511 37. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, Wang Q, Tan L, Wu W, Tang S, Xiong Z, Zheng S. 2020.
- 512 Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for 513 Detecting Antibodies against SARS-CoV-2. Journal of Clinical Microbiology 58.
- 514 38. Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A, Krogfelt KA, Jørgensen CS. 2020.
- 515 Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv 2020.04.09.20056325.
- 516 39. Chen Y, Guo Y, Pan Y, Zhao ZJ. 2020. Structure analysis of the receptor binding of 2019-nCoV.
  517 Biochemical and Biophysical Research Communications 525:135–140.
- 40. Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR. 2020. Phylogenetic Analysis and Structural
  Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive
  Activation Loop. J Mol Biol 432:3309–3325.
- 41. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J,
  Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L. 2020. Human
  neutralizing antibodies elicited by SARS-CoV-2 infection. Nature https://doi.org/10.1038/s41586020-2380-z.

It is made available under a CC-BY-ND 4.0 International license .

- 42. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L,
  Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S, Weiskopf D, Tse LV,
  Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM. 2020. The receptor binding
  domain of the viral spike protein is an immunodominant and highly specific target of antibodies in
  SARS-CoV-2 patients. Sci Immunol 5:eabc8413.
- 43. Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z,

531 Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang F, Wang Q, Gao GF, Yuan Z, Yan J.

532 2020. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature
533 https://doi.org/10.1038/s41586-020-2381-y.

44. Chia WN, Tan CW, Foo R, Kang AEZ, Peng Y, Sivalingam V, Tiu C, Ong XM, Zhu F, Young BE, Chen MIC, Tan Y-J, Lye DC, Anderson DE, Wang L-F. 2020. Serological differentiation between COVID-19 and
SARS infections. Emerging Microbes & Infections 9:1497–1505.

45. Grandjean L, Saso A, Ortiz A, Lam T, Hatcher J, Thistlethwaite R, Harris M, Best T, Johnson M,
Wagstaffe H, Ralph E, Mai A, Colijn C, Breuer J, Buckland M, Gilmour K, Goldblatt D, Team TC-SS.
2020. Humoral Response Dynamics Following Infection with SARS-CoV-2. medRxiv
2020.07.16.20155663.

- 46. Crawford KH, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, Shuey K, Casto AM, Fiala B, Wrenn S,
  Pettie D, King NP, Chu HY, Bloom JD. 2020. Dynamics of neutralizing antibody titers in the months
  after SARS-CoV-2 infection. medRxiv 2020.08.06.20169367.
- 47. McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, Leveille JM, Brunner MR,
  Holden K, Hopkins NS, Harris A, Kumpati JJ, Whitt MA, Lee JJ, Ostrosky-Zeichner L, Papanna R, LeBleu
  V, Allison J, Kalluri R. 2020. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

547 domain and nucleocapsid with implications on COVID-19 immunity. JCl Insight 548 https://doi.org/10.1172/jci.insight.142386.

- 48. Wan J, Xing S, Ding L, Wang Y, Gu C, Wu Y, Rong B, Li C, Wang S, Chen K, He C, Zhu D, Yuan S, Qiu C,
- 550 Zhao C, Nie L, Gao Z, Jiao J, Zhang X, Wang X, Ying T, Wang H, Xie Y, Lu Y, Xu J, Lan F. 2020. Human-
- 551 IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. Cell Reports 32:107918.
- 49. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. 2005. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 334:74–82.
- 50. Pak JE, Sharon C, Satkunarajah M, Auperin TC, Cameron CM, Kelvin DJ, Seetharaman J, Cochrane A,
  Plummer FA, Berry JD, Rini JM. 2009. Structural Insights into Immune Recognition of the Severe
  Acute Respiratory Syndrome Coronavirus S Protein Receptor Binding Domain. Journal of Molecular
  Biology 388:815–823.
- 559 51. Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. 2010. Potent and persistent antibody responses against 560 the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J 7:299.
- 52. Li L, Tong X, Chen H, He R, Lv Q, Yang R, Zhao L, Wang J, Xu H, Liu C, Chen G, Chen S, Li C, Qiao J, Yang
  J, Wu Y, Liu Z. 2020. Characteristics and serological patterns of COVID-19 convalescent plasma
  donors: optimal donors and timing of donation. Transfusion https://doi.org/10.1111/trf.15918.
- 53. Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ, Chen J,
  Castillo B, Leveque C, Towers DM, Lavinder J, Gollihar JD, Cardona J, Ippolito GC, Nissly RH, Bird IM,
  Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary IB, Cattadori IM, Hudson PJ, Joselyn N,
  Prugar L, Huie K, Herbert A, Bernard DW, Dye J, Kapur V, Musser JM. 2020. Relationship between

It is made available under a CC-BY-ND 4.0 International license .

- 568 Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent 569 Plasma. bioRxiv https://doi.org/10.1101/2020.06.08.138990.
- 570 54. Yao X-Y, Liu W, Li Z-Y, Xiong H-L, Su Y-Y, Li T, Zhang S-Y, Zhang X-J, Bi Z-F, Deng C-X, Li C-Y, Yuan Q,
- 571 Zhang J, Zhang T-Y, Wang Z-X, Ge S, Ningshao X. 2020. Neutralizing and binding antibody kinetics of
- 572 COVID-19 patients during hospital and convalescent phases. medRxiv 2020.07.18.20156810.
- 573 55. Pepper M, Rodda L, Netland J, Shehata L, Pruner K, Morawski P, Thouvenel C, Takahara K,
- 574 Eggenberger J, Hemann E, Waterman H, Fahning M, Chen Y, Rathe J, Stokes C, Wrenn S, Fiala B,
- 575 Carter L, Hamerman J, King N, Gale M, Campbell D, Rawlings D. 2020. Functional SARS-CoV-2-specific
- 576 immune memory persists after mild COVID-19. Res Sq https://doi.org/10.21203/rs.3.rs-57112/v1.
- 56. Dagotto G, Yu J, Barouch DH. 2020. Approaches and Challenges in SARS-CoV-2 Vaccine Development.
  Cell Host Microbe https://doi.org/10.1016/j.chom.2020.08.002.
- 579 57. Amanat F, Krammer F. 2020. SARS-CoV-2 Vaccines: Status Report. Immunity 52:583–589.
- 580 58. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC,
- 581 Greninger AL. 2020. Performance Characteristics of the Abbott Architect SARS-CoV-2 lgG Assay and
- 582 Seroprevalence in Boise, Idaho. J Clin Microbiol https://doi.org/10.1128/JCM.00941-20.
- 583 59. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth CW. 2020. 584 Clinical Performance of Two SARS-CoV-2 Serologic Assays. Clinical Chemistry hvaa120.
- 585 60. Tuaillon E, Bolloré K, Pisoni A, Debiesse S, Renault C, Marie S, Groc S, Niels C, Pansu N, Dupuy AM,
  586 Morquin D, Foulongne V, Bourdin A, Le Moing V, Van de Perre P. 2020. Detection of SARS-CoV-2
  587 antibodies using commercial assays and seroconversion patterns in hospitalized patients. J Infect
  588 81:e39–e45.

It is made available under a CC-BY-ND 4.0 International license .

- 589 61. Perkmann T, Perkmann-Nagele N, Breyer M-K, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D,
- 590 Sieghart D, Quehenberger P, Marculescu R, Mucher P, Strassl R, Wagner OF, Binder CJ, Haslacher H.
- 591 2020. Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on
- 592 specificity. Clin Chem https://doi.org/10.1093/clinchem/hvaa198.
- 593 62. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. 2020. Brief clinical evaluation of six high-594 throughput SARS-CoV-2 lgG antibody assays. J Clin Virol 129:104480.
- 595 63. Caini S, Bellerba F, Corso F, Díaz-Basabe A, Natoli G, Paget J, Facciotti F, De Angelis SP, Raimondi S,
- 596 Palli D, Mazzarella L, Pelicci PG, Vineis P, Gandini S. 2020. Meta-analysis of diagnostic performance
- 597 of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. 598 Eurosurveillance 25.
- 599 64. Chew KL, Tan SS, Saw S, Pajarillaga A, Zaine S, Khoo C, Wang W, Tambyah P, Jureen R, Sethi SK. 2020.
- 600 Clinical evaluation of serological IgG antibody response on the Abbott Architect for established 601 SARS-CoV-2 infection. Clinical Microbiology and Infection 26:1256.e9-1256.e11.
- 602 65. Herroelen PH, Martens GA, De Smet D, Swaerts K, Decavele A-S. 2020. Humoral Immune Response
  603 to SARS-CoV-2: Comparative Clinical Performance of Seven Commercial Serology Tests. American
  604 Journal of Clinical Pathology aqaa140.
- 605 66. Pflüger LS, Bannasch JH, Brehm TT, Pfefferle S, Hoffmann A, Nörz D, van der Meirschen M, Kluge S,
  606 Haddad M, Pischke S, Hiller J, Addo MM, Lohse AW, Wiesch JS zur, Peine S, Aepfelbacher M,
  607 Lütgehetmann M. 2020. Clinical evaluation of five different automated SARS-CoV-2 serology assays
  608 in a cohort of hospitalized COVID-19 patients. Journal of Clinical Virology 130:104549.
- 609 67. Xiao AT, Gao C, Zhang S. 2020. Profile of specific antibodies to SARS-CoV-2: The first report. J Infect
  610 https://doi.org/10.1016/j.jinf.2020.03.012.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

611 68. Zhou Q, Zhu D, Yan H, Quan J, Kuang Z, Zhang W, Huang L, Lei T, Liu J, Xiao B, Luo A, Sun Z, Li L. 2020.

- 612 A preliminary study on analytical performance of serological assay for SARS-CoV-2 lgM/lgG and
- application in clinical practice. medRxiv 2020.05.05.20092551.
- 69. Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. 2020. Analytical performances of a
  chemiluminescence immunoassay for SARS-CoV-2 lgM/lgG and antibody kinetics. Clinical Chemistry
  and Laboratory Medicine (CCLM) 1.
- 617 70. Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. 2020. Longitudinal
  618 Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19. The Journal of Applied
  619 Laboratory Medicine jfaa079.
- 520 71. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, Peng P, Liu X, Chen Z, Huang H, Zhang F, Luo W, Niu X,
  621 Hu P, Wang L, Peng H, Huang Z, Feng L, Li F, Zhang F, Li F, Zhong N, Chen L. 2020. Kinetics of SARS622 CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect 9:940–948.
- 623 72. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, Liao P, Qiu J-F, Lin Y, Cai X-F, Wang D-Q, Hu Y,
- Ren J-H, Tang N, Xu Y-Y, Yu L-H, Mo Z, Gong F, Zhang X-L, Tian W-G, Hu L, Zhang X-X, Xiang J-L, Du H-
- 625 X, Liu H-W, Lang C-H, Luo X-H, Wu S-B, Cui X-P, Zhou Z, Zhu M-M, Wang J, Xue C-J, Li X-F, Wang L, Li
- 626 Z-J, Wang K, Niu C-C, Yang Q-J, Tang X-J, Zhang Y, Liu X-M, Li J-J, Zhang D-C, Zhang F, Liu P, Yuan J, Li
- 627 Q, Hu J-L, Chen J, Huang A-L. 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19.
- 628 Nat Med 26:845–848.
- 73. Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, Chen Y, Gu B. 2020. Different longitudinal patterns of
  nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerging
  Microbes & Infections 9:833–836.

It is made available under a CC-BY-ND 4.0 International license .

632	74. Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y, Wang Q. 2020. Neutralizing Antibodies
633	Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. Clin Infect Dis
634	https://doi.org/10.1093/cid/ciaa721.
635	75. Hansen CB, Jarlhelt I, Pérez-Alós L, Hummelshøj Landsy L, Loftager M, Rosbjerg A, Helgstrand C,

- 636 Bjelke JR, Egebjerg T, Jardine JG, Sværke Jørgensen C, Iversen K, Bayarri-Olmos R, Garred P, Skjoedt
- 637 M-O. 2020. SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected
- 638 individuals. medRxiv 2020.07.27.20162321.

It is made available under a CC-BY-ND 4.0 International license .

#### 640

#### 641 TABLES

642

# 643 Table 1. Precision of the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays

VIDAS® SARS-CoV-2	Sample	Total number of measurements	Mean index	Repeatability (within-run precision)		Within-laboratory precision	
assay				SD	CV (%)	SD	CV (%)
	A (negative, high)	60	0.95	0.08	8.5	0.09	9.4
lgM	B (positive)	60	1.50	0.14	9.3	0.16	10.7
	C (positive)	60	5.78	0.42	7.3	0.46	8.0
lgG	D (negative, high)	60	0.88	0.03	3.8	0.04	4.5
	E (positive)	60	1.42	0.08	5.5	0.09	6.5
	F (positive)	60	8.04	0.48	5.9	0.55	6.9

644 Abbreviations: SD, standard deviation; CV, coefficient of variation

## Table 2. Cross-reactivity of human sera from patients with other infections or medical

## 647 conditions potentially interfering with the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays

	VIDAS <sup>®</sup> SAR	S-CoV-2 lgM	VIDAS <sup>®</sup> SARS-CoV-2 lgG	
Sample category	No. samples	No. positive	No. samples	No. positive
	tested	tests	tested	tests
Pregnant women	5	0	5	0
Antinuclear antibody (ANA) <sup>a</sup>	47	2	47	0
Rheumatoid factor	19	4	19	0
Human anti-mouse antibody (HAMA)	5	0	5	0
Borrelia burgdorferi	10	0	6	0
Haemophilus Influenzae B	5	0	5	0
Plasmodium falciparum	3	1	3	0
Toxoplasma gondii	10	0	6	0
Treponema pallidum	3	0	3	0
Trypanosoma cruzi	5	1	5	0
Hepatitis A virus (HAV)	3	0	3	0
Hepatitis B virus (HBV)	5	0	5	0
Hepatitis C virus (HCV)	5	0	5	0
Hepatitis E virus (HEV)	7	0	6	0
Herpes simplex virus (HSV)	6	0	6	0
Human immunodeficiency virus (HIV)	5	0	5	1
Cytomegalovirus (CMV)	4	0	3	0
Measles virus (MV)	4	0	3	0
Mumps virus (MuV)	1	0	3	0
Rubella virus (RuV)	10	0	6	0
Dengue virus (DENV)	3	0	3	0
West Nile virus (WNV)	4	0	3	0
Yellow fever virus (YFV)	4	0	3	0
Zika virus (ZIKV)	5	0	5	0
Adenovirus (AdV)	2	0	2	0
Metapneumovirus (MPV)	4	0	4	0
Rhinovirus/Enterovirus (RV/EnteroV) <sup>b</sup>	20	1	20	0
Influenza A and B virus (IAV/IBV)	30	0	30	0
Parainfluenza viruses 1/2/3 (PIV-1/2/3)	11	0	11	0
Respiratory syncytial virus A or B (RSV A or B)	13	0	13	1
Coronavirus NL63/HKU1 (CoV- <i>NL63/HKU1</i> ) <sup>c</sup>	9	1	9	0
Coronavirus 229E (CoV-229E)	7	0	7	0
Coronavirus OC43 (CoV-OC43)	2	0	2	0
Total	276	10	261	2

<sup>a</sup>Include anti-DNA, anti-SSA, anti-SSB and anti-Sm/RNP antibodies; <sup>b</sup>One out of 20 sera was from a patient with a bocavirus (BoV) co-

649 infection and was negative in both VIDAS® SARS-CoV-2 IgM and IgG assays; <sup>c</sup>Six out of the nine sera tested were from patients positive

650 for CoV-NL63 and three were from patients positive for CoV-NL63 and/or CoV-HKU1.

It is made available under a CC-BY-ND 4.0 International license .

# 652 Table 3. Specificity of the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays

VIDAS <sup>®</sup> SARS-CoV-2 serology testing	No. samples	No. negative results	Specificity	95% confidence interval (95% CI)
lgM	308	306	99.4%	97.7-99.9%
lgGª	989	988	99.9%	99.4-100.0%
Combined lgM/lgG <sup>b</sup>	308	306	99.4%	97.7-99.9%

<sup>a</sup>Specificity (95% CI) determined based on common samples (N=308) was 100.0% (98.8-100.0%); <sup>b</sup>combined test is negative when both IgM and IgG tests are negative

## Table 4. Positive percent agreement (PPA) of the VIDAS<sup>®</sup> SARS-CoV-2 IgM, IgG and combined

## 657 IgM/IgG test results of paired SARS-CoV-2-positive samples, according to the time from RT-

#### 658 **PCR-positive result**

VIDAS® SARS- CoV-2 serology testing	Time from RT-PCR- positive result	Median (range) time in days	No. samples <sup>ª</sup>	No. positive results	РРА	95% Cl
	0-7 days	2 (0-7)	110	49	44.5%	35.6-53.9%
	8-15 days	14 (8-15)	60	49	81.7%	70.1-89.4%
lgM (N=232)	16-23 days	20 (16-23)	38	31	81.6%	66.6-90.8%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	9	81.8%	52.3-94.9%
	0-7 days	2 (0-7)	110	50	45.5%	36.5-54.8%
	8-15 days	14 (8-15)	60	53	88.3%	77.8-94.2%
lgG (N=232)	16-23 days	20 (16-23)	38	36	94.7%	82.7-98.5%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	11	100.0%	71.5-100.0%
	0-7 days	2 (0-7)	110	59	53.6%	44.4-62.7%
Combined	8-15 days	14 (8-15)	60	57	95.0%	86.1-99.0%
Combined	16-23 days	20 (16-23)	38	38	100.0%	90.7-100.0%
Igivi/igo (iv=252)	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	11	100.0%	71.5-100.0%

659

<sup>a</sup>no more than one test result per patient per time period; <sup>b</sup>combined test is positive when at least one of IgM and/or IgG tests are

660 positive

#### Table 5. Positive percent agreement (PPA) of the VIDAS<sup>®</sup> SARS-CoV-2 IgM, IgG and combined 662

#### IgM/IgG test results of paired SARS-CoV-2-positive samples, according to the time from 663

#### 664 symptom onset

VIDAS <sup>®</sup> SARS-	Time from	Median	No.	No.	PPA	95% Cl
CoV-2 serology	symptom	(range) time	samples®	positive		
testing	onset	in days		results		
	0-7 days	5.5 (1-7)	22	7	31.8%	16.4-52.7%
	8-15 days	12 (8-15)	29	24	82.8%	65.5-92.4%
lgM (N=105)	16-23 days	18 (16-23)	26	26	100.0%	86.8-100.0%
	24-31 days	26 (24-30)	18	18	100.0%	81.5-100.0%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%
	0-7 days	5.5 (1-7)	22	7	31.8%	16.4-52.7%
	8-15 days	12 (8-15)	29	25	86.2%	69.4-94.5%
lgG (N=105)	16-23 days	18 (16-23)	26	25	96.2%	80.4-99.9%
	24-31 days	26 (24-30)	18	17	94.4%	74.2-99.0%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%
	0-7 days	5.5 (1-7)	22	8	36.4%	19.7-57.0%
Combined	8-15 days	12 (8-15)	29	26	89.7%	73.6-96.4%
lgM/lgG <sup>♭</sup>	16-23 days	18 (16-23)	26	26	100.0%	86.8-100.0%
(N=105)	24-31 days	26 (24-30)	18	18	100.0%	81.5-100.0%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%

665

<sup>a</sup>no more than one test result per patient per time period; <sup>b</sup> combined test is positive when at least one of |gM| and/or |gG| tests are 666 positive

- 668 Table 6. Positive and negative predictive values (PPV/NPV) at 5% prevalence of the VIDAS<sup>®</sup>
- 669 SARS-CoV-2 IgM, IgG and combined IgM/IgG test results, according to the time from symptom
- 670 **onset**

#### 671 **2** IgM, IgG and combined IgM/IgG test results, according to the time from symptom onset

VIDAS <sup>®</sup> SARS-CoV-2 serology	Time from	PPV <sup>a</sup> (95% CI)	NPV <sup>a</sup> (95% CI)
testing	symptom onset		
	0-7 days	72.1% (36.3-92.1%)	96.5% (95.4-97.4%)
	8-15 days	87.0% (62.5-96.4%)	99.1% (98.0-99.6%)
lgM	16-23 days	89.0% (67.1-97.0%)	100.0% (N/A) <sup>b</sup>
	24-31 days	89.0% (67.1-97.0%)	100.0% (N/A) <sup>b</sup>
	≥32 days	89.0% (67.1-97.0%)	100.0% (N/A) <sup>b</sup>
	0-7 days	100.0% (N/A) <sup>b</sup>	96.5% (95.4-97.4%)
	8-15 days	100.0% (N/A) <sup>b</sup>	99.3% (98.2-99.7%)
lgG	16-23 days	100.0% (N/A) <sup>b</sup>	99.8% (98.6-100.0%)
	24-31 days	100.0% (N/A) <sup>b</sup>	99.7% (98.1-100.0%)
	≥32 days	100.0% (N/A) <sup>b</sup>	100.0% (N/A) <sup>b</sup>
	0-7 days	74.7% (40-92.9%)	96.7% (95.6-97.6%)
	8-15 days	87.9% (64.5-96.7%)	99.5% (98.4-99.8%)
Combined lgM/lgG	16-23 days	89.0% (67.1-97.0%)	100.0% (N/A) <sup>b</sup>
	24-31 days	89.0% (67.1-97.0%)	100.0% (N/A) <sup>b</sup>
	≥ 32 days	89.0% (67.1-97.0%)	100.0% (N/A) <sup>b</sup>

672 <sup>a</sup>PPV and NPV were calculated at 5% prevalence and using values of specificity and sensitivity (PPA) determined on paired

673 VIDAS® SARS-CoV-2 IgM and IgG test results (N=308 for specificity, Table 3; N=105 for PPA, Table 5); <sup>b</sup>95% CI not calculable 674 (division by zero)



preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

**Figure 1. Study flow diagram.** Description of SARS-CoV-2-positive samples used to determine the positive percent agreement relative to the time of RT-PCR-positive test result and to the time of symptom onset. The number of and reason for sample exclusion are indicated in the white boxes. Included samples are indicated in greyed boxes. Altogether, out of the 405 collected samples (from 142 SARS-CoV-2-positive patients), 232 paired samples (i.e. tested with both VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays) from 130 patients with a documented date for the SARS-CoV-2-specific PCR-positive test, and 105 paired samples from 63 patients with a documented date of symptom onset were available.



Figure 2. Distribution of IgM (A) and IgG (B) index values obtained using the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays, respectively, in patients confirmed positive for SARS-CoV-2, according to the time from symptom onset. VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG index values of 105 paired samples from 63 SARS-CoV-2-positive patients (Table 5, Table S1 and Fig. 1) are displayed as Tukey box\_plots\_\_according\_to\_the\_time\_from\_symptom onset. No more than one patient's sample is included\_performed\_frame\_offee number of tested samples (N), and the median and interquartile range (IQR) of index values are indicated below each graph. The dashed line shows the positivity cut-off of both assays (i = 1.00).



Figure 3. Distribution of IgM (A) and IgG (B) index values obtained using the VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG assays, respectively, in hospitalized vs. non-hospitalized patients confirmed positive for SARS-CoV-2, according to the time from PCR-positive result. Out of the 232 paired samples (Tables 4 and S2), 15 samples from patients with an unknown hospitalization status were excluded from the analysis. VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG index values of 217 paired samples from 115 SARS-CoV-2-positive patients (100 samples from 54 hospitalized patients and 117 samples from 61 non-hospitalized patients) are depicted as Tukey box plots according to the time from RT-PCR-positive test result. No more than one patient's sample is included per time frame. The number of tested samples (N) and the median index are indicated below medRxiv preprint (which was not certified by per review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. each graph. The data shield clane oshows the positivity cut-off of both assays (i = 1.00). Differences between the groups of hospitalized and non-hospitalized patients were tested at each time frame (0-7, 8-15, 16-23 days post positive PCR) using a two-sided MWU-test; the respective p-values are displayed above each graph. No statistical testing was performed at 24-31 and  $\geq$  32 days due to the too low of lack of index values in the group of non-hospitalized patients at these time points.



Figure 4. Kinetics of IgM and IgG seroconversion in four selected hospitalized patients. VIDAS<sup>®</sup> SARS-CoV-2 IgM and IgG index values of four patients (A to D, respectively) measured over time after symptom onset are presented. The dashed line indicates the positivity cut-off of both assays (i = 1.00). Further patients' information is as follows: (A) the 78-year-old male patient was in the intensive-care unit (ICU) at all investigated time points, except at the first (day 7) and last (day 33) measurement time points; (B) the 77-year-old male patient was in ICU at all investigated time points; (C) the 43-year-old male patient was ICU at all investigated times, except at the last two measurement time points (day 71 and 74); (D) the 67-year-old male patient was in ICU at all investigated time points.